<DOC>
	<DOCNO>NCT02922348</DOCNO>
	<brief_summary>The investigator intend establish feasibility/acceptability pilot randomize trial compare hormone replacement therapy ( HRT ) combine oral contraceptive ( COCs ) woman premature ovarian insufficiency estimate difference quality life ( QOL ) serum hormone assay marker bone turnover/cardiovascular risk . At baseline , QOL survey administer serum testing perform . Patients randomize HRT COCs . Repeat test perform 3 6 month .</brief_summary>
	<brief_title>Hormone Replacement Premature Ovarian Insufficiency</brief_title>
	<detailed_description>Premature ovarian insufficiency ( POI ) term use describe woman 's ovary stop work normally natural age menopause . Early sequela POI include vasomotor symptom , vaginal dryness , mood swing insomnia due estrogen deficiency . Long-term sequelae loss bone mineral density cardiovascular risk carry considerable concern . While exogenous estrogen replacement recommend POI patient population , optimal regimen replacement clear . One approach hormone replacement therapy ( HRT ) mimic physiologic ovarian function full replacement dos estrogen ( either orally transdermally ) reach typical serum estradiol level menstruate woman ( approximately 104 pg/mL per day ) cyclic progestin therapy endometrial protection . Another approach use daily combine estrogen-progestin oral contraceptive ( COCs ) , ease administration increase social acceptability . To date , study perform compare two treatment method term quality life measure ( vasomotor symptom , bleed profile , sexual dysfunction , satisfaction contraception ) , endocrine function , bone turnover cardiovascular risk POI patient . In proposal , investigator intend establish feasibility acceptability pilot randomize control trial compare traditional HRT COCs woman POI evaluate difference quality life measure , hormone assay , bone turnover cardiovascular risk treatment arm . The investigator hypothesize acceptability feasibility pilot trial high difference detect measured variable treatment arm . Demonstration feasibility acceptability pilot would allow pursuit large trial identification superior treatment regimen would meaningful impact short long-term care patient population .</detailed_description>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Primary Ovarian Insufficiency</mesh_term>
	<mesh_term>Gonadal Dysgenesis</mesh_term>
	<mesh_term>Turner Syndrome</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Norgestimate</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Contraceptives , Oral , Combined</mesh_term>
	<criteria>Female patient , Between 1445 year age Postmenarchal Presence uterus POI define : change menstrual function ( oligomenorrhea and/or amenorrhea ) , elevate serum serum follicle stimulate hormone ( FSH ) , low serum estradiol concentration , estrogen deficiency symptom . Pregnancy lactation within previous 3 month Use hormonal contraception replacement within previous 3 month Any contraindication oral contraceptive pill hormone replacement therapy per current drug label . These could include , limited : history venous thromboembolism , estrogensensitive cancer history , regular cigarette smoke history active liver disease , etc . Patients screen pregnancy urine HCG test time screen</criteria>
	<gender>Female</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>premature ovarian failure</keyword>
	<keyword>hormone replacement</keyword>
</DOC>